A
AbSci
Biotech & Life Sciences · Vancouver, United States · Founded 2011 · IPO 2021
The global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry MoreLess
AbSci is a pioneering company in the biotech industry, focused on revolutionizing protein expression and biomanufacturing. The company operates in the biopharmaceutical market, serving clients that include pharmaceutical companies, biotech firms, and research institutions. AbSci's core innovation lies in its advanced protein expression platform, which features a semi-oxidizing cytoplasm and a dual inducible promoter system. These technologies allow for precise control over protein production rates, leading to higher quality and efficiency in drug manufacturing.
One of AbSci's standout offerings is SoluPure, a chromatography-free purification method that simplifies the downstream processing of proteins. This method removes bottlenecks typically associated with traditional purification techniques, making the production process faster and more cost-effective. AbSci's high-throughput workflow can generate cell lines that produce folded, active protein products in as little as three months, significantly reducing the time and resources needed for drug development.
AbSci's business model is built around providing cutting-edge biomanufacturing solutions that introduce efficiencies and cost savings to the biotech industry. The company makes money by partnering with pharmaceutical and biotech companies, offering them proprietary technologies and services that enhance their drug discovery and manufacturing processes. By doing so, AbSci aims to replace traditional mammalian expression platforms, such as CHO cells, with its more efficient and scalable solutions.
The company is supported by a group of experienced investors and is driven by a team of passionate, imaginative, and accomplished scientists. These professionals are dedicated to challenging established industry practices and creating extraordinary tools for drug discovery and manufacturing.
In summary, AbSci is a disruptive force in the biotech industry, offering innovative solutions that streamline protein production and purification, ultimately transforming how life-changing biologics are made.
Keywords: Biotech, Protein Expression, Biomanufacturing, Drug Discovery, SoluPure, Purification, High-Throughput, Cytoplasm, Promoter System, Biopharmaceutical.
Talent graph
AbSci's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where AbSci has talent and traffic
team presence
across markets
Patent intelligence
$7M patent portfolio · 25 active families
Where AbSci concentrates vs peers
Each axis is a top-10 topic across AbSci and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about AbSci
An AI-synthesized read of the highest-engagement posts about AbSci on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AbSci on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.






















